No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MERC Mercer International
- 10.080
- -0.170-1.66%
Trading Apr 26 15:44 ET
673.85MMarket Cap-2761P/E (TTM)
10.450High10.060Low64.92KVolume10.310Open10.250Pre Close658.96KTurnover0.12%Turnover RatioLossP/E (Static)66.85MShares10.45052wk High1.06P/B550.38MFloat Cap6.95752wk Low0.30Dividend TTM54.60MShs Float16.706Historical High2.98%Div YieldTTM3.81%Amplitude0.179Historical Low10.151Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Mercer International (MERC) Is Attractively Priced Despite Fast-paced Momentum
Mercer International Inc. Price Target Raised to $10.50/Share From $8.50 by Raymond James
Mercer International Inc. Price Target Raised to $10.50/Share From $8.50 by Raymond James
Shareholders in Mercer International (NASDAQ:MERC) Have Lost 36%, as Stock Drops 8.0% This Past Week
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any portfolio, there are likely to be some stocks that fall short of that benchmark.
Mercer International Inc. Is Maintained at Hold by TD Securities
Mercer International Inc. Is Maintained at Hold by TD Securities
Express News | Mercer International Inc : TD Cowen Raises Target Price to $10.5 From $10
Mercer International Inc. Announces Conference Call for First Quarter 2024 Results
April 16, 2024 / All Stories, Company News, Featured, Investors Mercer International Inc. announces conference call for first quarter 2024 results NEW YORK, NY, April 16, 2024 Mercer Internationa
Comments
Mercer's acquisition of MDK is a strategic move to bolster its services for ultrahigh-net-worth clients, a rapidly expanding segment. The deal also aims to broaden Mercer's footprint in the Pacific Northwest market.
Mercer Makes Ultrahigh-Net-Worth Play With Acquisition of $2.5 Billion Seattle Firm -- Barrons.comThe fall in revenue and lack of profitability for Mercer International contribute to a pessimistic market viewpoint. However, the company's substantial dividend payments paint a more comprehensive picture, when considering total shareholder return.
ColumnsTop upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more
Upgrades
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
•$Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
•$Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
8
$Mercer International(MERC.US$ The head of India's leading medical research institute said on Wednesday that Mercer's new oral crown drug molnupiravir has "significant safety issues" that may prevent it from joining the country's list of viral treatments.
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg